News >

Published Selinexor Data Show Sustained Survival in Heavily Pretreated Myeloma

Gina Columbus @ginacolumbusonc
Published: Wednesday, Aug 21, 2019

Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of medicine (hematology and medical oncology), of the Tisch Cancer Institute at Mount Sinai School of Medicine

Sundar Jagannath, MD

Selinexor (Xpovio) in combination with twice-weekly dexamethasone led to a median overall survival (OS) of 15.6 months in patients with heavily pretreated multiple myeloma who had a minimal response or better to the novel agent compared with 1.7 months in those whose disease progressed or had unevaluable responses, according to data from the phase IIb STORM trial that were published in the New England Journal of Medicine.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x